VPHIF (Valeo Pharma) EBIT per Share: $-0.13 (TTM As of Jul. 2024)


VPHIF Valeo Pharma Inc VPHIF
12 GF Score
Price $0.00
View Full Analysis

What is Valeo Pharma EBIT per Share?

Valeo Pharma VPHIF -99.00% 12 EBIT per Share is $-0.13 as of Jul. 2024. GuruFocus rates VPHIF with a GF Score™ of 12/100.

Valeo Pharma's EBIT per Share for the three months ended in Jul. 2024 was $-0.03. Its EBIT per Share for the trailing twelve months (TTM) ended in Jul. 2024 was $-0.13.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Valeo Pharma's EBIT per Share or its related term are showing as below:

VPHIF's 3-Year EBIT Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Valeo Pharma's EBIT for the three months ended in Jul. 2024 was $-3.08 Mil.

Valeo Pharma  (OTCPK:VPHIF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Valeo Pharma EBIT per Share Related Terms

Valeo Pharma EBIT per Share Historical Data

* Premium members only.

The historical data trend for Valeo Pharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valeo Pharma EBIT per Share Chart

Valeo Pharma Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
EBIT per Share
Get a 7-Day Free Trial -0.05 -0.05 -0.15 -0.19 -0.12

Valeo Pharma Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.04 -0.03 -0.03 -0.03
VPHIF
12GF Score
Valeo Pharma Inc VPHIF
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valeo Pharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Valeo Pharma's EBIT per Share for the fiscal year that ended in Oct. 2023 is calculated as

EBIT per Share(A: Oct. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-10.223/86.117
=-0.12

Valeo Pharma's EBIT per Share for the quarter that ended in Jul. 2024 is calculated as

EBIT per Share(Q: Jul. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-3.076/98.675
=-0.03

EBIT per Share for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.13 mean?
Valeo Pharma (VPHIF) has a EBIT per Share of $-0.13 as of Jul. 2024. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Valeo Pharma and its competitors.
Is Valeo Pharma's EBIT per Share too high?
Valeo Pharma's current EBIT per Share is $-0.13. Overall, Valeo Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Valeo Pharma's EBIT per Share compare to ZTS?
Valeo Pharma's EBIT per Share of $-0.13 can be compared against companies in the Drug Manufacturers industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Valeo Pharma and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valeo Pharma's current EBIT per Share is $-0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valeo Pharma stock overvalued right now?
Valeo Pharma (VPHIF) has a current EBIT per Share of $-0.13. The current EBIT per Share is $-0.13. Valeo Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Valeo Pharma (VPHIF), the current EBIT per Share is $-0.13 as of Jul. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Valeo Pharma Business Description

Address 16667, Hymus Boulevard, Kirkland, QC, CAN, H9H 4R9
Valeo Pharma Inc is a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and hospital specialty products. Its product portfolio includes medicines for Respiratory/Allergy, Ophthalmology, Neurology, and Oncology.
12GF Score

Get the complete analysis for VPHIF

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price